Results 91 to 100 of about 5,926 (192)

Abstract 1781: EGFR amplification-A candidate predictive biomarker of PARP inhibitor Talazoparib sensitivity in gliomas

, 2017
Poly (ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARP is a promising strategy for targeting cancers with defective DNA-damage repair.
John de Groot, Dimpy Koul, Erik Sulman, Xiaolong Li, Emmanuel Martinez-Ledesma, Ningping Feng, Feng Gao, Jie Ding, Shaofang Wu, Siyuan Zheng, Roel Verhaak, W.K.Alfred Yung   +11 more
core   +1 more source

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

, 2017
Poly ADP-ribose polymerase (PARP) inhibitors, including talazoparib, potentiate temozolomide efficacy in multiple tumor types; however, talazoparib-mediated sensitization has not been evaluated in orthotopic glioblastoma (GBM) models.
Karen E. Parrish, Brett L. Carlson, Paul A. Decker, Jann N. Sarkaria, Ryo Kawashima, Mark A. Schroeder, Ann C. Mladek, Kenneth Chang, Yuqiao Shen, Sani H. Kizilbash, Andrew A. Protter, Gaspar J. Kitange, Ying Feng, Katrina K. Bakken, William F. Elmquist, Shiv K. Gupta   +15 more
core   +1 more source

Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib

eBioMedicine
Loss of heterozygosity (LOH) diminishes genetic diversity within cancer genomes. A tumour arising in an individual heterozygous for a functional and a loss-of-function (LoF) allele of a gene occasionally retain only the LoF allele. This can result in deficiency of specific protein activities in cancer cells, creating unique differences between tumour ...
Xiaonan Zhang, Natallia Rameika, Lei Zhong, Verónica Rendo, Margus Veanes, Snehangshu Kundu, Sandro Nuciforo, Jordan Dupuis, Muhammad Al Azhar, Ioanna Tsiara, Pauline Seeburger, Shahed Al Nassralla, Viktor Ljungström, Richard Svensson, Ivaylo Stoimenov, Per Artursson, Markus H. Heim, Daniel Globisch, Tobias Sjöblom   +18 more
openaire   +5 more sources

Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid Tumors

Cancers
Malignant rhabdoid tumors (MRTs) are among the most aggressive and treatment-resistant malignancies affecting infants, originating in the kidney, brain, liver, and soft tissues. The 5-year event-free survival rate for these cancers is a mere 20%. In nearly all cases of MRT, the SMARCB1 gene (occasionally SMARCA4)—a pivotal component of the SWI/SNF ...
Elena Mironova, Sebastian Molinas, Vanessa Del Pozo, Abhik M. Bandyopadhyay, Zhao Lai, Dias Kurmashev, Eric L. Schneider, Daniel V. Santi, Yidong Chen, Raushan T. Kurmasheva   +9 more
openaire   +2 more sources

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric Cancer Models in the Pediatric Preclinical Testing Program

, 2015
Purpose: Inhibitors of PARP, an enzyme involved in base excision repair, have demonstrated single-agent activity against tumors deficient in homologous repair processes. Ewing sarcoma cells are also sensitive to PARP inhibitors, although the mechanism is
Houghton, PJ, Carol, H, Reynolds, CP, Gorlick, R, Keir, ST, Lyalin, D, Lock, RB ; https://orcid.org/, Smith, MA, Kurmasheva, RT, Kang, MH, Billups, CA, Kolb, EA, Maris, JM   +12 more
core   +1 more source

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Computational Evaluation of Novel PARP-1 Inhibitors for Breast Cancer: Docking, Molecular Dynamics, MM/GBSA, DFT and ADMET Calculations

Pharmaceuticals
Background/Objectives: Poly (ADP-ribose) polymerase (PARP1) has emerged as a promising therapeutic target in human breast cancer particularly in BRCA1/2 mutation carriers where a synthetic lethal interaction leads to massive tumor cell death upon ...
Charmy Twala, Penny Govender, Ephraim Marondedze, Krishna Govender   +3 more
doaj   +1 more source

Talazoparib [PDF]

, 2020
openaire   +1 more source

885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

Regular and Young Investigator Award Abstracts, 2023
Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang   +18 more
openaire   +2 more sources

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends

Cancer Management and Research
Bicky Thapa,1,* Navonil De Sarkar,2– 4,* Subhajit Giri,2,3 Komal Sharma,2– 4 Mingee Kim,5 Deepak Kilari1 1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; 2Medical College of Wisconsin Cancer Center ...
Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D   +5 more
doaj